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Abstract:  This  review  discusses  the  isolation,  structural  elucidation,  and  biological 
activities of halogenated indole alkaloids obtained from marine invertebrates. Meridianins 
and  related  compounds  (variolins,  psammopemmins,  and  aplicyanins),  as  well  as 
aplysinopsins  and  leptoclinidamines,  are  focused  on.  A  compilation  of  the 
13C-NMR 
spectral data of these selected natural indole alkaloids is also provided. 
Keywords:  marine  invertebrates;  halogenated  indole  alkaloids;  structure  elucidation; 
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1. Introduction  
Marine organisms are among the most promising sources of bioactive molecules [1–3]. Unlike 
terrestrial organisms, marine organisms often produce halogenated secondary metabolites, particularly 
alkaloids  [4].  The  majority  of  halogenated  metabolites  contain  bromine  and  they  are  especially 
abundant in the marine environment, whereas chlorinated compounds are preferably synthesized by 
terrestrial organisms. In contrast to brominated and chlorinated metabolites, iodinated and fluorinated 
compounds are quite rare [5,6]. 
Marine life produces most of the 4,000 known natural organohalogens. Almost all of the 2,100 natural 
organobromine compounds are found in marine organisms. Although there is much less bromide than 
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chloride  in  the  oceans  (bromine  65  mg/L;  chlorine  19,000  mg/L),  marine  organisms  can  oxidize 
bromide  more  easily  for  incorporation  into  organic  compounds.  Nevertheless,  a  large  number  of 
marine metabolites contain both bromine and chlorine [7,8]. 
Ecological  pressures  within  the  marine  ecosystem,  including  significant  competition  for  space, 
deterrence  of  predation,  and  a  high  level  of  symbiosis  between  different  species,  are  partially 
responsible  for  the  unique  secondary  metabolism  of  marine  life  that  give  rise  to  the  chemical 
components of these actions and interactions [9,10]. 
The  presence  of  halogen  substituents  in  many  natural  products  profoundly  influences  their 
biological  activity  [6].  Examples  of  such  biologically  active  compounds  are  the  antibiotics 
vancomycin, chloramphenicol aureomycin, and salinosporamide A; a proteasome inhibitor currently 
under clinical trials for multiple myeoloma treatment; and the antimicrobial rebeccamycin [6,8]. 
Among  halogenated  alkaloids,  bromoalkaloids  are  the  most  widely  distributed  group  of  natural 
compounds. This group is predominantly found in marine eukaryotes, is significantly rarer in prokaryotic 
microorganisms, and is practically absent from terrestrial plants and animals [4]. Iodoalkaloids compose 
a rare group of natural compounds that has been isolated from marine organisms [4]. 
The  first  iodinated  indoles  found  in  a  natural  source,  either  marine  or  terrestrial,  were  the 
plakohypaphorines A–C (1–3, Figure 1) isolated from the Caribbean sponge Plakortis simplex [8,11]. 
Figure 1. Structures of plakohypaphorines A, B, and C (1–3). 
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A huge diversity of indole alkaloids are frequently found in marine invertebrates and they have 
been considered lead compounds for the discovery of new drugs  in medicinal chemistry [9,12]. The 
biological activity of marine indole alkaloids is clearly a product of the unique functionality and 
elements involved in the biosynthesis of marine natural products. For instance, bromination of  many 
natural products has the potential to increase biological activity significantly [9]. 
In this report we have focused  on the halogenated indole  alkaloids  from marine invertebrates, 
particularly meridianins; their related compounds variolins, psammopemmins, and aplicyanins as well 
as  the  aplysinopsins  and  leptoclinidamines.  Also  summarized  are  the  methods  of  structure 
determination, observed biological activities and a compilation of 
13C-NMR spectral data is provided. 
1.1. Biohalogenation  
The  halogenation  of  natural  products  is  a  frequent  modification  of  secondary  metabolism  that 
allows for optimization of the bioactivity of small molecules, providing evolutionary advantage [6]. 
Many  biohalogenation  enzymes  have  been  isolated  and  characterized.  Chloroperoxidase, 
bromoperoxidase, iodoperoxidase, and the enzymes involved in the biosynthesis of fluoroacetic acid 
(fluoroacetaldehyde dehydrogenase and 5’-fluorodeoxyadenosine synthase) are some examples [8]. Mar. Drugs 2010, 8                       
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Halogenating  enzymes  have  been  discovered  in  a  broad  range  of  organisms  and  they  can  be 
grouped  into  two  main  classes:  (i)  highly  substrate-specific  halogenases  requiring  dioxygen  for 
enzymatic  activity  and  (ii)  less  specific  haloperoxidases  (HPO)  utilizing  hydrogen  peroxide.  In 
dioxygen-dependent  halogenases,  either  flavin  (FADH2-dependent  halogenases)  or  R-ketoglutarate 
(non-heme FeII/R-ketoglutarate/O2- dependent halogenases) are found to function as co-substrates. 
Furthermore, methyltransferases are involved in the formation of the carbon halogen bonds of CH3Cl, 
CH3Br,  and  CH3I,  and  other  enzymes  requiring  S-adenosyl-L-methionine  as  catalyst  have  been 
identified to be involved in fluorination and chlorination [13]. 
In the recent years, the understanding of biohalogenation processes has been extended extraordinarily. 
The cloning and sequencing of biosynthetic gene clusters have revealed new mechanisms leading to 
halogen incorporation and stimulated detailed mechanistic studies of these enzymes [6,8]. New groups of 
halogenating enzymes have been discovered and investigated at both biochemical and genetic levels. 
Each group of these enzymes performs halogenation reactions on chemically distinct substructures using 
a specific reaction mechanism. For instance, some FADH2-dependent halogenases are directly involved 
in the halogenation of aromatic compounds, recognizing tryptophan or indole moieties, while other 
groups of FADH2-dependent halogenases participate in the halogenation of aliphatic compounds [13]. 
1.2. Meridianins 
Meridianins are marine alkaloids which were first isolated from the Ascidian Aplidium meridianum [14]. 
Structurally, the meridianins comprise a brominated and/or hydroxylated indole nucleus substituted at 
C-3 by a 2-aminopyrimidine. Seven meridianins A–G (4–10) have been discovered so far. Bromine 
substitution occurs on position 5 for meridianin C (6), on position 6 for B (5) and D (7), on position 7 for 
E (8), and on positions 5 and 6 for F (9) (Figure 2). 
Figure 2. Structures of meridianins 4–10. 
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Meridianins have been described as potent inhibitors of various protein kinases (Table 1) and they 
display  antitumor activity.  Meridianins B (5)  and  E  (8)  are  the  most  potent  and,  for  this  reason 
meridianin E was selected for further selectivity studies on 25 highly purified kinases [15]. Essentially, 
all physiological processes and most human diseases involve protein phosphorylation. Phosphorylation 
of proteins on serine, threonine, and tyrosine residues by the 518 protein kinases encoded in the human 
genome  constitutes  one  of  the  major  mechanisms  used  by  cells  to  regulate  their  metabolism  and 
functions. The recent appreciation of the implication of abnormal protein phosphorylation in many Mar. Drugs 2010, 8                       
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human  diseases  has  sparked  considerable  interest  in  the  search  for  pharmacological  inhibitors  of 
kinases [16–18]. 
Table 1. Effects of meridianins A–G (4–10) on the activity of protein kinases (IC50 in M). 
Protein kinase 
Meridianins 
A  B  C  D  E  F  G 
CDK1/cyclin B  2.50  1.50  3.00  13.00  0.18  20.00  150.00 
CDK5/p25  3.00  1.00  6.00  5.50  0.15  20.00  140.00 
PKA  11.00  0.21  0.70  1.00  0.09  3.20  120.00 
PKG  200.0  1.00  0.40  0.80  0.60  0.60  400.00 
GSK-3β  1.30  0.50  2.00  2.50  2.50  2.00  350.00 
CK1  nt 
1  1.00  30.00  100.00  0.40  nt 
1  nt 
1 
1 nt: not tested. 
Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a 
cause  or  consequence  of  diseases.  For  instance,  among  the  518  human  kinases  cyclin-dependent 
kinases  (CDK)  have  attracted  considerable  interest  given  their  involvement  in  many  essential 
physiological pathways and numerous abnormalities in multiple human diseases, especially cancer and 
neurodegenerative diseases such as Alzheimer’s and Parkison’s diseases [16,18,19]. 
Investigations of structure-activity relationships of meridianins have revealed that the substitution at 
C-5 and the methylation of the indole nitrogen are important for either kinase inhibitory activity or  
in vitro antiproliferative activities. Related to CDK1 and CDK5, the bromine substitution on position 7 
and the hydroxyl on position 4 provide the best inhibitory activity. A single bromine substitution on 
position 5 or 6 of the indole ring results in considerable improvement in potency. On the other hand, 
two bromide substitutions slightly reduce the inhibitory potency [20,21]. 
Meridianins  B,  C,  D,  and  E  (5–8)  display  cytotoxicity  toward  LMM3  (murine  mammalian 
adenocarcinoma cell line) with IC50 values of 11.4 M, 9.3 M, 33.9 M, and 11.1 M, respectively 
[14].  Certainly,  meridianins  constitute  a  new  scaffold  exhibiting  micromolar  inhibition  of  protein 
kinases from which more potent and selective inhibitors can be designed [15]. 
Meridianins  are  closely related  to  the variolins, a class of marine alkaloids from the Antarctic 
sponge Kirkpatrickia varialosa [22,23]. 
1.3. Variolins  
In 1994, the Blunt, Munro and Faulkner laboratories reported the isolation and structural elucidation 
of the variolins from the rare Antarctic sponge Kirkpatrickia varialosa [22,23]. Variolins are the first 
examples of either terrestrial or marine natural products with a pyrido[3’,2’:4,5]pyrrolo[1,2-c]pyrimidine 
system.  This  rare  pyridopyrrolopyrimidine  skeleton  has  made  the  variolins  an  interesting  class  of 
alkaloids from both structural and biogenetic viewpoints. Variolins can also be considered as guanidine-
based alkaloids in which the guanidine moiety is found in the guise of a 2-aminopyrimidine ring [24–26]. 
The isolated compounds included variolin A (11), variolin B (12), N(3')-methyl tetrahydrovariolin 
B (13), and variolin D (14), the latter of which was reported to be an artifact of the extraction process Mar. Drugs 2010, 8                       
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produced by aerial oxidation of the variolins (Figure 3). This type of compounds exhibit a potent 
cytotoxic activity against P388 murine leukemia cell line, also being effective against Herpes simplex 
type I. Variolin B (12) is the most active of this family of natural products [26]. 
Figure 3. Structures of variolins 11–15. 
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There  has  been  considerable  interest  in  the  synthesis  of  variolins  due  to  the  novelty  of  their 
structures, not to mention their biological properties and low natural occurrence [25]. To date, four 
total syntheses of variolin B have been reported in the literature [21,27–33], and the preparation of the 
synthetic deoxyvariolin B (15) has also been described [34,35]. The synthesis of new derivatives of 
variolin B with different substituents at positions C-5 and C-7 has also been reported [26]. 
Although the natural variolins isolated are not halogenated, this type of skeleton along with the 
structure  of  meridianins  have  been  an  inspiration  for  the  synthesis  of  the  hybrid  meriolins  1–14  
(16–29, Figure 4), including the halogenated meriolins 10 (25) and 11 (26) [18]. 
1.4. Meriolins 
Variolins with a pyridopyrrolopyrimidine system and meridianins possessing a pyrimidyl-substituted 
indole skeleton bear some structural similarities. Through a combination of the common features of 
these natural products, a new class of 7-azaindole-containing analogues (16–29) known as meriolins 
has been designed by Meijer and co-workers [21].  
Meriolins [3-(pyrimidin-4-yl)-7-azaindoles], a chemical hybrid of the variolins and meridianins, 
display  potent  inhibitory  activity  toward  CDKs  (especially  CDK2  and  CDK9).  This  class  of 
compounds also exhibit better antiproliferative and proapoptotic properties in cell cultures compared 
with their ‘‘inspirational parent’’ molecules [18,19]. Mar. Drugs 2010, 8                       
 
 
1531 
Figure 4. Structures of meriolins 16–29. 
N
R1
R2 N
R3
N
N
R4
(16) Meriolin 1                H               H     H     NH2
(17) Meriolin 2              OH              H     H     NH2
(18) Meriolin 3             OMe             H     H     NH2
(19) Meriolin 4              OEt              H     H     NH2
(20) Meriolin 5              OPr              H     H     NH2
(21) Meriolin 6             OiPr              H     H     NH2
(22) Meriolin 7       O(CH2)2OMe     H     H     NH2
R1             R2    R3     R4
(23) Meriolin 8        OH        H     Me    NH2
(24) Meriolin 9       OMe       H     Me    NH2
(25) Meriolin 10       Cl         H      H      NH2
(26) Meriolin 11        H         Br     H      NH2
(27) Meriolin 12     OMe       H      H     SMe
(28) Meriolin 13       OH       H      H        H
(29) Meriolin 14     OMe       H      H        H
R1        R2     R3      R4
 
The resemblance between the chemical structures of the two natural products meridianins and 
variolin B has inspired the synthesis of a hybrid structure referred to as meriolins, which display better 
antiproliferative and proapoptotic properties in human tumor cell cultures than their parent molecules. 
A selectivity study performed on 32 kinases has shown that, compared with variolin B, meriolins 
exhibit enhanced specificity toward CDKs, with marked potency on CDK2 and CDK9 [19].  
The structures of pCDK2/cyclin A/meriolin 3, pCDK2/cyclin A/meriolin 5, and pCDK2/cyclin 
A/variolin B complexes have been determined by X -ray crystallography, which revealed that these 
inhibitors bind within the ATP binding site of the kinase, but in different orientations [18,19,21]. 
All synthesized meriolins 1–14, along with variolin B as a reference, were tested on seven purified 
protein  kinases,  namely  CDK1/cyclin  B,  CDK2/cyclin  A,  CDK5/p25,  CDK9/cyclin  T,  GSK-3/, 
CK1ʴ/, and DYRK1A (Table 2). Structure-Activity studies complemented with the crystal structure 
have provided some clarification on the action mechanisms of these molecules on their CDK target [18]. 
Table 2. Effects of variolin B (12) and meriolins 1(16), 10 (25), and 11 (26) on the activity 
of protein kinases (IC50 in M). 
Protein kinase  Variolin B  Meriolin 1  Meriolin 10  Meriolin 11 
CDK1/cyclin B  0.06  0.78  0.24  2.20 
CDK2/cyclin A  0.08  0.09  0.06  1.3 
CDK5/p25  0.09  0.51  0.23  0.68 
CDK9/cyclin T  0.026  0.026  0.05  1.00 
GSK-3/β  0.07  0.63  2.00  30.0 
CK1  0.005  0.2  3.0  1.3 
DYRK1A  0.08  0.13  0.13  0.3 
In the case of meriolin 11 (26), addition of a bromide atom at C-5 leads to a drop in inhibitory 
activity for almost all tested protein kinases, but this effect is particularly pronounced against CDK9 
and GSK-3. CDK1, CDK2, and CDK5 are less affected by the bromide addition. Moreover, addition 
of a chloride atom at C-4 in meriolin 10 (25) results in decreased potency compared to the non-
halogenated meriolin 1 (16). Taken together, these observations suggest that meriolins constitute a Mar. Drugs 2010, 8                       
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new  CDK  inhibitory  scaffold  with  promising  antitumor  activity,  and  they  can  be  derived  from 
molecules initially isolated from marine organisms [19]. 
1.5. Psammopemmins 
Psammopemmins represent an unusual group of natural products isolated as an amine salt from an 
Antarctic marine sponge Psammopemma sp and they comprise three structurally related compounds 
designated  psammopemmins  A–C  (30–32,  Figure  5).  All  of  the  psammopemmins  incorporate  the  
4-hydroxyindole  moiety  substituted  at  the  3-position  by  an  unusual  2-bromopyrimidine  system. 
Compounds  containing  4-oxygenated  indoles  often  display  potent  pharmacological  properties. 
Psammopemmins B (31) and C (32) contain further bromination on the indole ring. Unfortunately, the 
small amounts of material isolated so far have precluded any further investigation of their biological 
activity. The assigned structure of the psammopemmin family likewise remains to be confirmed by 
total synthesis [21,36]. 
Figure 5. Structures of psammopemmins 30–32 and aplycianins 33–38. 
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1.6. Aplicyanins 
A  new  family  of  indole  alkaloids  was  recently  isolated  from  the  Antarctic  tunicate  
Aplidium cyaneum by Reyes and co-workers [37]. The aplicyanins A–F (33–38, Figure 5) contain a 
bromoindole nucleus and a 6-tetrahydropyrimidine substituent at C-3. The main structural variations 
present in aplicyanins include additional bromination of indole ring and the presence of N-methoxy 
group as shown in aplicyanins C–F (35–38). The aplicyanins share a common 3-(pyrimid-4-yl)indole 
structure  with  meridianins  A–G  (4–10),  the  psammopemmins  A–C  (30–32)  and  variolins  A–D  
(11–14). The tetrahydropyrimidine system of the aplicyanins has a stereocenter at C 4’, in contrast 
with the planar pyrimidine ring of the meridianins [21].  
Aplycianins are cytotoxic to the human tumor cell lines MDA-MB-231 (breast adenocarcinoma), 
A549 (lung carcinoma), and HT-29 (colorectal carcinoma). They also exhibit antimitotic activity [38]. 
Lastly, given the high cytotoxicity typical of bromoindole derivatives, the presence of a bromoindole 
moiety in some aplicyanins warrants their investigation as anticancer drugs. Recently, the first total 
synthesis of ()-aplicyanins A, B, and E and 17 analogues has been reported [38]. Mar. Drugs 2010, 8                       
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Regarding the aplicyanin family of indole alkaloids, the six variants of aplicyanins isolated were 
evaluated  for  cytotoxicity  against  a  panel  of  three  human  tumor  cell  lines,  colon  (HT-29),  lung  
(A-549), and breast (MDA-MB-231). The antimitotic activity of these variants has also been assessed. 
Cytotoxic activity in the submicromolar range as well as antimitotic properties have been found for 
aplicyanin B (34), D (36), and F (38), with IC50 values in the low to sub-M range. On the other hand, 
aplicyanin  A  (33)  and  C (35)  proved to  be  inactive at the highest  concentrations  tested, whereas 
aplicyanin E (37) displayed weak cytotoxic properties (Table 3). These results indicate a key role for 
the presence of the acetyl group in the biological activity of the aplicyanin family [37]. 
Table 3. Cytotoxicity (GI50 values reported in M) and antimitotic activity (IC50, mM) of 
aplicyanins B (34), D (36), E (37), F (38) and () aplicyanin A, B, and E. 
Compound 
Cell lines  Antimitotic 
Activity  A-549  HT-29  MDA-MB-231 
Aplicyanin B  0.66  0.39  0.42  1.19 
Aplicyanin D  0.63  0.33  0.41  1.09 
Aplicyanin E  8.70  7.96  7.96  nt
2 
Aplicyanin F  1.31  0.47  0.81  0.18–0.036 
()-aplicyanin A  0.27  0.11  0.27  nt 
()-aplicyanin B  0.51  0.33  0.98  nt 
()-aplicyanin E  na 
1  na  10.9  nt 
1 na: not active; 
2nt: not tested. 
 
In order to establish the structure-activity relationships of the aplicyanins, the total synthesis of  
()-aplicyanins A, B, and E, plus 17 analogues was carried out by Sí sa and co-workers in 2009 [38]. 
The compounds were again screened for cytotoxicity against the same three human tumor cell lines 
used for the natural compounds. Racemic ()-aplicyanin A exhibited activity in the submicromolar 
range, despite the inactivity of the corresponding natural product. Racemic ()-aplicyanin B was as 
active as  its  corresponding natural product in all three tested cellular lines, whereas aplicyanin E 
maintained the activity only towards the MDA-MB-231cell line (Table 3). The decreased cytotoxicity 
observed for racemic aplicyanin E compared to the natural product, indicates that one enantiomer is 
more active than the other [38].  
Fourteen of the synthesized compounds also exhibited considerable cytotoxic activity, and these 
results suggest that the bromine at position 5 of the indole nucleus strongly favors antiproliferative 
activity,  and  the  acetyl  group  at  the  imine  nitrogen  also  acts  in  some  compounds.  These  results 
demonstrate the potential of aplycianins structure as a scaffold for anticancer drug discovery [38]. 
1.7. Aplysinopsins 
In 1977, Kazlauskas, Rymantas, and co-workers reported the isolation of aplysinopsin (39) from the 
dictoyoceratid  sponge  Aplysinopsis  [39,40].  Aplysinopsin  derivatives  belong  to  a  class  of  indole 
alkaloids and they have also been found in other dictyoceratid and astrophorid sponges as well as in 
dendrophylliid scleractinian corals [41]. Additionally, aplysinopsins have been described in anemone, 
in a symbiotic association, and in a mollusk that feeds on the coral Tubastrea coccinea [39]. Mar. Drugs 2010, 8                       
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Figure 6. Structures of aplysinopsins 39–53. 
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The halogenated aplysinopsins natural derivatives (Figure 6) contain a 6-bromoindole moiety, and 
an iminoimidazolidinone or imidazolidinedione system, both varying in terms of the number and position 
of N-methylation. The iminoimidazolidinone portion of compounds 39–45 are shown as the exocyclic 
imino tautomer. Only compound 44 contains an additional bromine at the C-5 of the indole core. The 
aplysinopsins derivatives also differ in terms of the presence and absence of the C-8-C-1’ double bond. 
Thus,  aplysinopsins  with  C-8-C-1’  double  bonds,  the  most  abundant  type,  can  occur  as  two 
geometrical  isomers  (E/Z).  Also,  it  has  been  observed  that  (Z)-aplysinopsins  are  generally  less 
abundant than the (E)-isomers [41,42]. Aplysinopsins substituted at the nitrogen atom of the indole 
ring and dimers have also been isolated or identified, although compound 45 could be an artifact [43–45]. 
Aplysinopsins  exhibit  cytoxicity  towards  tumour  cells,  as  well  as  some  antimalarial  and 
antimicrobial activities. However, properties related to neurotransmission modulation seem to be the 
most significant pharmacological feature of these compounds. Aplysinopsins have the potential to Mar. Drugs 2010, 8                       
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influence monoaminooxidase (MAO) and nitric oxide synthase (NOS) activities. They have also been 
found to modulate serotonin receptors [39]. 
Aplysinopsin-type  compounds  have  been  reported  from  multiple  sources,  with  brominated 
aplysinopsins being described from sponges [46–49], corals [41–45], anemone, and mollusks [50,51]. 
Natural aplysinopsins differ in the bromination pattern of the indole ring. Almost all natural occurring 
aplysinopsins display halogenations at the position 6 of the indole ring. The only exception is the 
compound 5,6-dibromo-2’-demethylaplysinopsin (44), which an additional bromine atom at C-5 [39]. 
The compounds 6-bromo-2’-de-N-methylaplysinopsin (40) and 6-bromoaplysinopsin (41) isolated 
from the Jamaican sponge Smenospongia aurea displayed high-affinity [
3H]antagonist binding from 
cloned  human  serotonin  5-HT2C  receptors  expressed  in  a  mammalian  cell  line  (Ki =  2.3  M  and  
Ki = 0.33 M, respectively). Compound 41 also displayed high-affinity [
3H]antagonist binding from 
the 5-HT2A receptor subtype (Ki = 2.0 M) compared with serotonin affinity values Ki = 0.32 M at the 
5-HT2A receptor and Ki = 0.13 M at the 5-HT2C receptor [46].  
The structure-activity relationship data reveal a role for the R1, R2, and R3 functional groups at 
positions 6, 2’, and 3’, respectively, in the binding to human serotonin 5-HT2 receptors. The length of 
the alkyl chain at the R3 position as well as the bromination at position R1 seems to be important for 
activity.  In  addition,  bromination  at  the  R1  position  is  also  relevant  for  the  binding  affinity  of 
aplysinopsins and for their selective binding to the 5-HT2C receptor subtype, since both compounds 40 
and 41 are brominated and both selectively bind the 5-HT2C receptor subtype over the 5-HT2A receptor 
subtype. Methylation at the R2 position facilitates binding to the 5-HT2A receptor subtype. A larger 
number of analogues will be required to confirm this proposed structure-activity relationship [46]. 
Pharmacological and  genetic  studies  have  revealed  that  these  receptors  influence feeding, glucose 
homeostasis, and the energy efficiency of physical activity, sleep, sensory processing and learning, 
affective functioning, and the pathophysiology of several neuropsychiatric disorders [52,53]. 
6-Bromo-2’-de-N-methylaplysinopsin  (40)  and  6-bromoaplysinopsin  (41)  have  also  been  tested  
in  vitro  against  a  D6  clone  of  Plasmodium  falciparum  for  their  in  vitro  antimalarial  activity.  
6-Bromoaplysinopsin (41) exhibited activity at 0.34 g/mL with selective index 14 (S.I. = [IC50 (Vero 
cells)/IC50 (P. falciparum)], while 6-bromo-2’-de-N-methylaplysinopsin (40) showed moderate activity 
at  1.1  g/mL  with  low  selectivity.  Moreover,  compound  40  inhibited  the  antimalarial  target 
plasmepsin II enzyme with IC50 53 M (FRET) and 66 M (FP) [46]. 
Additionally, 6-bromoaplysinopsin (41) has been reported to be involved in the symbiotic association 
between Radianthus kuekentbali (sea anemone) and Amphiprum perideraion (anemone fish) [50]. 
A number of aplysinopsin alkaloids have also been evaluated for their neuromodulatory activity in 
two types of nitric oxide synthase (NOS) isozymes. Nitric oxide (NO) is known to be an important 
second  messenger  having  numerous  functions  which  regulate  many  physiological  processes;  
e.g.,  inflammation,  blood  pressure  regulation,  platelet  adhesion,  neurotransmission,  and  defense 
mechanisms. The biosynthesis of NO is catalyzed by nitric oxide synthase (NOS), which is classified 
into three isoforms: inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS). 
Therefore, a selective inhibitor of NOS isozymes would be expected to have significant therapeutic 
potential  as  a  neuromodulator  [47].  6-Bromo-2’-de-N-methylaplysinopsin  (40)  and  the  isomers  
5,6-dibromo-2’-demethylaplysinopsin Z-44 and E-44 isolated from the sponge Hyrtios erecta display 
selective  inhibitory  activity  against  nNOS,  with  100%  inhibition  of  nNOS  at  125  g/mL  [47]. Mar. Drugs 2010, 8                       
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Compounds  Z-44  and  E-44  showed  no  inhibitory  activity  against  iNOS.  In  turn,  aplysinopsin  40 
inhibited only 7.5% of iNOS activity at a concentration of 125 g/mL [47]. 
Regarding the antimicrobial potential of halogenated aplysinopsins, Koh and Sweatman [54] have 
reported the screening of the Australian coral Tubastraea faulkneri extract for antimicrobial assay 
against seven species of microbes (Vibrio alginolyticus, V. harveyi, V. parahaemolyticus, Photobacterium 
damsela,  Alteromonas  rubra,  Staphylococcus  aureus,  and  Synechococcus  sp).  Aplysinopsin  (39),  
6-bromoaplysinopsin  (41),  6-bromo-2’-de-N-methylaplysinopsin  (40),  and  its  dimer  52  were  the 
compounds isolated accounting for 72% of the activity of the T. faulkneri methanol extract. This study 
also suggested that these aplysinopsins are toxic to the larvae of other coral species that are potential 
competitors and could act as allelochemicals [54]. The aplysinopsins 46–49 isolated from the sponge 
Thorectandra sp were evaluated for antimicrobial activity against Staphylococcus epidermidi. All of 
the compounds were found to have either weak or moderate minimum inhibitory concentrations (MIC) 
ranging from 6.25 to 100 μg/mL as compared to the standard vancomycin (0.625 g/mL) [48]. 
1.8. Leptoclinidamines 
Three new indole alkaloids, namely leptoclinidamines A–C (54–56, Figure 7), have been recently 
isolated from the Australian ascidian Leptoclinides durus [55].  
Figure 7. Structures of leptoclinidamines 54–56. 
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The  leptoclinidamines  A  (54)  and  B  (55)  both  contain  an  indoleglyoxylic  acid  attached  to  an  
L-arginine residue, while leptoclinidamine C (56) contains the rare 1,3-dimethyl-5-(methylthio)histidine 
moiety  attached  to  a  6-bromoindole-3-carboxylic  acid.  The  structure  of  leptoclinidamine  A  was 
confirmed by total synthesis. The compounds were tested for bioactivity against chloroquine-sensitive 
and chloroquine-resistant strains of the malarial parasite Plasmodium falciparum, for trypanosomal 
activity against Trypanosoma brucei, and for cytotoxicity against the cancerous cell line HeLa and 
noncancerous HEK 293 cells, but none of the compounds were bioactive [55]. Mar. Drugs 2010, 8                       
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Figure 8. Structures of chartelline, chartellamide, securamines and securines 57–68. 
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1.9. Chartelline, Chartellamide, Securamines and Securines 
Chartelline  A,  Chartellamide  A,  B  and  C  (57–59,  Figure  8)  are  unusual  -lactam-imidazole 
alkaloids  isolated  from  the  marine  bryozoans  Chartella  papyracea  (Flustridae)  [56,57].  In  
addition,  other  halogenated  indole-imidazole  alkaloids  named  securamines  were  isolated  from 
Securiflustra securifrons (Pallas), another member of this family. The halogenated securamines B (61) 
and C (62) only differ from securamines A (60) and D (63), respectively by the presence of a bromine 
substituent in the benzene ring [58]. Securamines E (64), F (65) and G (68) were isolated from the 
same bryozoans S. securifrons (Pallas) [59]. Securine A (66) and B (67) were obtained by dissolving 
securamine A (60) and B (61), respectively, in DMSO-d6 [59]. Mar. Drugs 2010, 8                       
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Table  4.  Comparison of the biological activity of the main natural halogenated indole 
alkaloids meridianins, psammopemmins, aplicyanins, and aplysinopsins. 
Compound  Biological Activity 
Meridianins 
Meridianin B (5)  Inhibition of protein kinases; Cytotoxicity [14,15] 
Meridianin C (6)  Inhibition of protein kinases; Cytotoxicity [14,15] 
Meridianin D (7)  Inhibition of protein kinases; Cytotoxicity [14,15] 
Meridianin E (8)  Inhibition of protein kinases; Cytotoxicity [14,15] 
Meridianin F (9)  Inhibition of protein kinases [14] 
Psammopemmins 
Psammopemmin B (31)  nt 
1 
Psammopemmin C (32)  nt  
Aplicyanins 
Aplicyanin A (33)  na 
2 
Aplicyanin B (34)  Cytotoxicity and antimitotic activity [37] 
Aplicyanin C (35)  na 
Aplicyanin D (36)  Cytotoxicity and antimitotic activity [37] 
Aplicyanin E (37)  Cytotoxicity [37] 
Aplicyanin F (38)  Cytotoxicity and antimitotic activity [37] 
Aplysinopsins 
6-bromo-2’-de-N-methylaplysinopsin (40)  Antimalarial [46]; Serotonin receptors modulator [46] 
Inhibitor of nitric oxide synthase (nNOS) [47] 
6-bromoaplysinopsin (41)  Antimalarial [46]; Serotonin receptors modulator [46] 
Allelochemical [54] 
6-bromo-4’-de-N-methylaplysinopsin (42)  nt 
6-bromo-4’-demethyl-3’-N-methylaplysinopsin (43)  nt 
5,6-dibromo-2’-demethylaplysinopsin (44)  Inhibitor of nitric oxide synthase (nNOS) [47] 
6-bromo-1’,8-dihydro-aplysinopsin (46)  Antimicrobial [48] 
6-bromo-1’-hydroxy-1’,8-dihydroaplysinopsin (47)  Antimicrobial [48] 
6-bromo-1’-methoxy-1’,8-dihydroxyaplysinopsin (48)  Antimicrobial [48] 
6-bromo-1’-ethoxy-1’,8-dihydroxyaplysinopsin (49)  Antimicrobial [48] 
6-bromo-3’-deimino-3’-oxoaplysinopsin (50)  nt 
6-bromo-3’-deimino-2’,4’-bis(demethyl)-3’-
Oxoaplysinopsin (51) 
nt 
Dimer of 6-bromo-2’-de-N-methylaplysinopsin (52)  Antimicrobial [54] 
Tubastrindole A (53)  - 
1 nt: not tested. 
2na: not active. 
1.10. Structural Elucidation 
This section reports a compilation of the 
13C chemical shifts of the halogenated marine indole 
alkaloids  derivatives,  meridianins  (5–9),  psammopemmins  (30  and  32),  aplicyanins  (33–38), 
aplysinopsins  (40–41,  43–44,  46–51,  53),  and  leptoclinidamines  (56),  which  have  in  common the 
presence of a 3-substituted indole nucleus. Additionally, the 
13C data of 10 and 39 are presented for 
comparison of the 
13C chemical shifts with
 halogenated examples. The literature data are listed in 
Tables 5, 6, 7 and 8. The solvent (A = DMSO-d6, B = CD3OD, and C = CDCl3) and references are 
shown in the first line of the tables. 
Inspection of the 
13C-NMR data of compounds 5, 8, 30 and 32 as compared with 10 (Table 5) 
reveals that introduction of a hydroxyl group in the C-4 indole moiety results in downfield signals at 
the ʱ carbon. Additionally, comparison of the 
13C data of meridianin G (10), which bears only a  Mar. Drugs 2010, 8                       
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3-substituted  indole  core,  with  the  other  bromine  indole  derivatives  shows  that  introduction  of  a 
bromine in the indole skeleton results in upfield signals at the ʱ carbon. 
The meridianin family
 skeleton can be recognized by the typical 
1H-NMR signals, as for example, 
in the case of compound 10: a pair of doublet for the pyrimidine protons (ʴ 7.02 and 8.05, J = 5.5 Hz), 
together with a singlet for H-2, the typical pattern of a 3-substituted indole nucleus. The 
13C-NMR 
downfield signals at ʴ C-2’, C-4’, and CH-6’ corroborate the presence of 2-aminopyrimidine at C-3 in 
compounds 5–10 [60]. 
The  basic  difference  between  the  psammopemmins  and  the  meridianins  is  the  presence  of  a  
5’-substituted 4’-amino-2’-bromopyrimidine at C-3 of the indole nucleus. The distinguishing 
1H-NMR 
signals of the heterocyclic ring of the psammopemmins class
 can be recognized by the signals at ʴ 7.12 
(d, J = 5.4 Hz) and 8.12 (br d, J = 5.4 Hz), attributed to the pyrimidine proton H-6’ and to NH at 
position 1’, as in the case of compound 30. The 
13C-NMR downfield signals at ʴ C-2’, C-4’, and  
C-5’confirm the presence of 5'-substituted 4’-amino-2’-bromopyrimidine [28]. 
The  aplicianins’ 
13C-NMR  spectra  differ  from  those  of  the  meridianins  and  psammopemmins 
because of the presence of the signals due to a guanidine group at low field (C-2’) and three chemicals 
shifts  at  upfield,  ascribed  to  C-4’(CH),  C-5’  (CH2),  and  C-6’  (CH2).  Additionally,  the 
1H-NMR 
coupling  constants  of  the  6-tetrahydropyrimidine  protons  are  important  to  establish  the  difference 
between aplicyanins, meridianins, and psammopemmins [37]. 
Aplysinopsins (39–41, 43–44), with the iminoimidazolidinone substituted at the C-3 of the indole 
core, normally show a 
1H-NMR spectrum with signals due to N-methyl groups in the range of ʴ 3.0 to 
3.5 (s, 3H), as well as a singlet characteristic of an olefinic proton in the  6.38–6.46 range. The  
13C  NMR  spectrum  reveals  the  signals  for  two  olefinic  carbons  C-8  (CH)  and  C-1’(C),  methyl, 
guanidine, and amide carbonyl, as well as those of the indole ring, as already mentioned [43,47,48]. 
Analysis of the 
13C data of 39, which bears a 3-substituted indole core, and comparison with data of 
the other bromine indole derivatives show that the presence of bromine in the indole moiety results in 
upfield signals at the carbon ʱ. 
The  spectra  of  aplysinopsins  (50–51)  differ  in  terms  of  the  signals  at  C-8,  C-3’,  and  C-5’,  if 
compared with data for 3-iminoimidazolidinone, where C=NH (C-3’) is replaced by C=O (C-3’) [41]. 
The E or Z-configuration of the double bond at C-8 could be assigned on the basis of a 
1H, 
13C 
heteronuclear coupling constant. The coupling constant value obtained for the E isomer was larger 
than in the Z [41,42]. The geometry of the C-8-C-1’ olefin could be determined by comparison of the 
chemical shift of the H-2 proton and C-8 carbon. In the Z isomer, the ʴ values of C-8 and H-2 were 
upfield compared to the values obtained for the E isomer [41,42,47]. Aplysinopsin type compounds 
without substituents at N-2’ are predominantly of Z configuration, whereas the converse is true for 
compounds bearing a methyl group at N-2’. Although it is important to note that, Z and E aplysinopsin 
alkaloids undergo rapid isomerization [41,42,61]. 
Comparison of the 
13C-NMR data of 46–49 with previous aplysinopsins reveals that the C-8 and  
C-1’ signals are shifted upfield according to R1 at C-1’, thereby confirming that the double bond at  
C-8-C-1’ is absent. Segraves and Crews considered that 48 and 49 are artifacts formed from 47 during 
the extraction process [48]. 
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Table 5. 
13C chemical shifts (ʴ in ppm) of meridianins, psammopemmins, and aplicyanins halogenated derivatives. 
Carbon  5  6  7  8  9  10  30  32  33  34  35  36  37 
Solvent 
Ref. 
A 
14 
A 
14 
A 
14 
A 
14 
B 
60 
B 
60 
A 
25 
A 
25 
B 
37 
B 
37 
B 
37 
B 
37 
B 
37 
2  129.9  129.6  129.2  129.2  131.6  129.1  128.3  128.8  125.3  125.6  123.8  124.1  124.7 
3  113.7  113.3  114.8  116.1  114.9  115.4  113.7  113.6  113.6  113.8  112.0  111.2  112.3 
3a  114.0  127.1  124.5  115.2  127.6  126.8  114.3  113.9  124.1  127.8  124.3  124.1  123.5 
4  153.0  124.6  124.3  152.0  127.7  122.7
  152.0  152.9  121.9  121.8  122.5  122.4  124.6 
5  108.8  113.4  123.1  107.3  118.4
  123.4
  105.4  108.4  115.2  114.3  114.4  114.6  119.3 
6  116.7  124.7  113.9  126.7  117.1  121.9
  124.3  116.4  125.9  126.1  126.9  127.1  116.4 
7  105.3  113.9  114.5  92.6  117.5  112.8  102.3  105.0  114.5  114.6  111.4  111.5  114.6 
7a  139.7  135.9  138.0  136.9  138.5  138.9  139.2  139.5  137.2  137.2  132.7  132.7  133.6 
2'  160.7  163.6  163.6  160.2  165.3  165.6  161.7  161.6  155.7  152.3  155.7  152.4  155.7 
4'  160.8  162.3  162.3  161.8  163.9  165.6  160.7  159.7  48.1  48.2  47.6  47.7  47.4 
5'  104.6  105.4  105.4  104.8  107.1  107.6  158.3  158.8  28.3  26.9  28.3  26.6  28.3 
6'  157.1  157.2  157.2  159.0  156.2  157.5  104.3  104.3  38.6  38.6  38.4  38.2  38.3 
CH3CO                    173.9    174.0   
CH3CO                    24.1    24.1   
OCH3                      66.8  66.7  67.0 
Table 6. 
13C chemical shifts (ʴ in ppm) for halogenated aplicyanin 38 and aplysinopsins derivatives. 
Carbon  38  39  40 (Z)  40 (E)  41  43 (Z)  43 (E)  44 (Z)  44 (E)  50 (E)  51 (Z)  51 (E) 
Solvent 
Ref. 
B 
37 
A 
62 
A 
42 
A 
42 
A 
43 
A 
42 
A 
42 
A 
47 
A 
47 
A 
41 
A 
41 
A 
41 
2  125.0  127.4  129.6  129.0  127.7  129.9  129.0  130.6  132.6  129.3  127.5  130.1 
3  111.5  108.4  111.9  110.7  108.7  112.0  110.8  108.3  108.2  108.7  108.7  108.9 
3a  123.2  127.8  125.7  126.7  126.9  125.7  126.8  127.8  128.4  127.5  126.3  127.3 Mar. Drugs 2010, 8                       
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Table 6. Cont. 
Carbon  38  39  40 (Z)  40 (E)  41  43 (Z)  43 (E)  44 (Z)  44 (E)  50 (E)  51 (Z)  51 (E) 
Solvent 
Ref. 
B 
37 
A 
62 
A 
42 
A 
42 
A 
43 
A 
42 
A 
42 
A 
47 
A 
47 
A 
41 
A 
41 
A 
41 
4  124.5  118.1  121.0  119.9  119.6  121.1  120.0  123.6  122.5  120.2  120.1  119.2 
5  119.5  119.5  122.4  122.5  121.8  122.4  122.5  116.9  116.9  122.6  122.9  122.8 
6  116.6  121.8  114.5  114.4  121.8  114.5  114.5  115.2  115.2  114.0  115.0  114.6 
7  114.6  111.8  114.3  114.4  114.0  114.3  114.4  116.8  117.2  114.6  114.4  115.0 
7a  133.6  135.7  136.7  136.5  136.2  136.5  136.5  135.8  135.8  136.5  136.6  136.5 
8    102.8  106.1  113.3  101.5  106.5  113.9  108.9  115.1  107.5  101.0  106.5 
1'    126.5  136.9  134.9  126.9  136.9  136.6  135.7  135.7  125.1  124.9  125.4 
2’  152.3                       
3'  26.8  150.8  157.7  155.0  162.1  157.1  154.7  155.9  152.7  152.8  155.4  153.4 
4’  47.6                       
5'  26.8  162.3  169.0  167.0  150.4  169.0  167.1  163.2  160.8  162.0  167.3  163.9 
6'  38.1                       
2'-NCH3    27.0      24.4  27.8  27.8      24.3     
4'- NCH3    24.9  25.6  25.6  26.6  25.5  25.4  26.0  26.0  26.3     
OCH3  67.1                       
CH3CO  174.0                       
CH3CO  24.1                       
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Table 7. 
13C chemical shifts (ʴ in ppm) for halogenated aplysinopsins and leptoclinidamines derivatives. 
Carbon  46  47  48  49  53  56  Carbon  46  47  48  49  53  56 
Solvent 
Ref. 
B 
48 
B 
48 
B 
48 
B 
48 
ni 
1 
44 
A 
55 
4'          119.7   
2  124.8  125.1  125.4  125.4  123.3  129.0  5'  171.8  171.9  169.7  170.0  124.8   
3  106.5  105.3  104.6  104.7  115.0  109.4  6'          117.3   
3a  125.7  125.6  125.6  125.6  126.4  124.9  7'          115.9   
4  119.3  119.3  119.4  119.0  120.1  122.9  7a'          137.4   
5  121.9  122.0  122.1  122.0  121.5  123.4  8'          44.5   
6  114.7  114.8  114.9  114.9  125.9  114.6  9'          72.3   
7  113.9  114.0  114.0  114.0  113.0  114.8  11'          159.0   
7a  137.2  137.1  137.2  137.2  139.5  137.0  13'          172.5   
8  29.4  30.1  30.1  30.4  27.6  164.1  2'-NCH3  24.7  25.3  25.6  25.6     
9          72.3    4'- NCH3  24.1  24.6  24.7  24.6     
10            50.0  10-NCH3          33.1   
11          161.6  25.7  12-NCH3          26.6   
12            136.4  13-SCH3            18.6 
13          174.0  125.9  14-NCH3            33.5 
15            138.1  16-NCH3            34.2 
17            172.2  10'-NCH3          28.4   
1'  64.0  89.0  94.3  93.8      12'-NCH3          26.5   
2'          125.6    OCH3      52.3       
3'  158.1  156.6  157.2  157.0  104.4    OCH2        61.5     
3'a          127.7    CH3        13.7     
1 ni: not informed. 
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Table 8. 
13C chemical shifts (ʴ in ppm) for halogenated chartelline, chartellamides, securamines and securines derivatives. 
Carbon  58  59  60  61  62  63  64  65  66  67  68 
Solvent 
Ref. 
C 
57 
C 
57 
C 
58 
C 
58 
C 
58 
C 
58 
C 
59 
C 
59 
A 
58 
A 
58 
C 
59 
2  120.4  120.6  127.4  127.1  135.9  136.1  136.4  135.9  130.2  130.3  48.3 
3  109.5  108.1  95.1  95.3  101.6  101.2  101.2  101.5  100.9  103.6  96.3 
4  130.5  130.8  115.8  116.0  187.5  188.0  187.3  187.2  121.1  121.5  140.7 
6  133.2  116.6  122.5  121.1  166.6  166.7  166.4  166.0  125.0  127.6  156.8 
8  126.6  129.5  145.5  144.8  85.6  85.7  85.4  84.7  135.6  135.3  80.7 
9  65.9  65.2  41.6  41.9  44.0  43.9  44.2  43.7  40.6  40.8  39.2 
10  41.6  41.6  64.9  64.6  59.4  59.5  58.7  52.1  71.2  70.9  61.4 
11  45.9  46.8  48.6  48.3  41.8  41.7  41.9  42.8  30.8  30.8  41.0 
12  67.9  70.5  87.4  87.4  89.2  89.1  88.0  89.8  132.7  133.9  87.9 
14  141.5  141.1  147.0  148.0  147.0  145.7  148.0  146.9  134.4  134.5  147.5 
15  117.6  117.6  109.3  112.2  114.7  111.1  113.5  114.7  110.9  113.2  114.6 
16  125.9  126.0  129.0  122.3  123.1  129.4  120.6  123.0  120.5  114.1  122.3 
17  132.5  132.5  119.9  122.5  124.9  121.9  128.0  124.9  118.1  119.4  123.5 
18  119.4  119.4  123.9  125.0  125.6  124.6  123.8  125.5  117.5  121.1  125.2 
19  124.8  124.7  127.8  126.7  128.0  128.8  126.3  127.9  128.5  126.0  130.4 
20  67.4  67.6  50.0  49.4  45.0  45.3  46.8  44.9  105.7  106.3  45.6 
21  47.8  48.0  34.1  33.8  34.2  34.4  32.6  34.2  30.7  30.6  33.8 
22  162.5  162.1  172.8  172.2  170.3  170.5  170.0  170.0  169.4  169.1  171.2 
23  164.9  164.1  19.0  18.9  17.2  17.3  17.1  18.6  19.8  19.8  15.4 
24  15.4  17.1  31.9  31.8  21.1  21.1  21.1  22.6  28.7  28.7  21.1 
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The 
13C-NMR  data  of  compound  53  indicates  the  presence  of  two  indoles  and  two 
iminoimidazolidinones.  Biogenetically,  this  compound  could  be  formed  from  an  enzymatic  
Diels–Alder  cycloaddition  of  two  molecules  of  aplysinopsin,  which  were  probably  derived  from 
tryptophan and guanidine, followed by some modifications [44]. 
The structure of leptoclinidamine C (56) has been established as a 3,6-disubstituted indole and a  
β-substituted alanine by 1D and 2D NMR data. The 
13C data
 indicate the presence of two N-methyl 
groups at C-14 and C-16; a third methyl group at C-13 is attributable to an S-methyl. As mentioned, 
the chemical shift of the quaternary carbon C-6 (ʴ 114.6) indicates that the bromine was substituted at 
this position [55]. 
2. Conclusions 
In recent decades the number of new isolated natural compounds, many of which contain halogen, 
has increased significantly as a consequence of improved collection methods (scuba diving and remote 
submersibles for accessing deep water organisms), selective bioassays, new separation and purification 
techniques,  and  powerful  identification  methods  such  as  multi-dimensional  NMR  spectroscopy,  
high-resolution mass spectrometry, and X-ray diffraction [8,3]. The assignment of carbon signals of a 
given isolated compound by comparison with the data of known compounds is an important tool for 
the discovery of novel natural compounds, when the 
13C-NMR data of appropriate model compounds 
are  available.  This  was  the  case  with  meridianins  A–E,  which  were  deduced  by  2D  NMR 
spectroscopic  methods  in  combination  with  comparison  to  literature  data  reported  for  the  related 
natural products the psammopemmins. The indole alkaloids are a class of marine natural products 
displaying  unique  promising  properties  for  the  development  of  new  drug  leads,  and  they  are  a 
wonderful challenge to synthetic chemists. The majority of marine indole alkaloids are rather simple 
compounds. However, some of the indole alkaloids carry unique structural features. Bacteria and algae 
have yielded simple halogenated indoles, while more complicated structures have been isolated from 
marine sources [9]. Over the past 5 years there has clearly been an increasing interest in the isolation, 
determination of the biological and ecological significance, and synthesis of meridianins, aplysinopsis, 
and  analogues,  as  confirmed  by  number  of  articles  and  reviews  about  these  marine  natural  
molecules [21,39,63]. Among the different classes of compounds reported here, the protein kinase 
inhibitors meridianins deserve prominence. Along with variolins, these compounds have inspired the 
design  of  the  synthetic  hybrid  meriolins,  which  constitute  a  new  CDK  inhibitory  scaffold  with 
promising antitumor activity. On the other hand, aplycianins because of their pronounced antimitotic 
and  cytotoxic  potential,  have  been  considered  a  novel  model  for  anticancer  drug  discovery. 
Unfortunately, the biological potential of psammopemmins and the recently isolated leptolinidamines 
are unknown so far. Finally, aplysinopsins show specific toxicity for cancer cells; however, the most 
potent  pharmacological  activity  of  aplysinopsins  is  related  to  modulation  of  the  central  nervous 
system. An interesting fact in all these types of indole skeletons covered here is that halogenations 
generally occur at C-5, sometimes at C-6, or at both C-5 and C-6 of the indole ring. The bromination 
of many of the mentioned natural products could be associated with increased biological activity [9].  
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